Genixcure

About Genixcure

Genixcure is a South Korean biotechnology company specializing in the development of gene therapy delivery platforms. Founded in April 2019 as A&L Bio and later renamed, the company is led by CEO Moon Hong-sung. Genixcure has positioned itself uniquely in the biotech market by focusing on creating and licensing adeno-associated virus (AAV) vectors—the delivery vehicles for gene therapies—rather than developing the therapies themselves. This business model is designed to be low-risk and high-return, licensing its platform to pharmaceutical firms for upfront fees, milestone payments, and a share of future revenue.

The company's core technology is its Cell-specific AAV Research Engine (CARE™), a platform that develops novel AAV vectors. It utilizes a proprietary AI-based screening system called InsightMiner™ to engineer next-generation AAV capsids with enhanced targeting efficiency, improved safety profiles, and the ability to cross the blood-brain barrier. A key focus is creating vectors that avoid the liver, mitigating the risk of liver toxicity that has been a major hurdle in gene therapy clinical trials. The technology is built on primate gene data, which provides a significant advantage in designing precise carriers for human therapies.

Genixcure's pipeline includes therapeutic programs for rare and neurodegenerative diseases such as Lafora disease, ALS, and Alzheimer's disease. Its lead candidate for Lafora disease, GXC301, has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. FDA. The company serves other research institutions and biotech firms by providing non-GMP AAV production services for preclinical studies. Genixcure has established multiple partnerships, including license-out deals with major South Korean pharmaceutical companies and collaborations with entities like Samsung Medical Center and ToolGen.